Your Navigation:PCAR > Abstract
Search pcar
检索项:
检索词:
Abstract
Pharmaceutical Care and Research: 2019; 19(2):114-117
DOI: 10.5428/pcar20190209
Clostridium difficile bacteremia:one case report and literature analysis
1. ZHENG Xiaoxiao1(1.Department of Pharmacy,Xuzhou First People’s Hospital,Jiangsu Xuzhou 221002,China xiaoxiao-0912@163.com)
2. XU Shengqiu1(1.Department of Pharmacy,Xuzhou First People’s Hospital,Jiangsu Xuzhou 221002,China )
3. CHEN Erzhen2(2.Emergency Intensive Care Unit,Ruijin Hospital Affiliated to School of Medicine,Shanghai Jiaotong University,Shanghai 200025,China chenerzhen@hotmail.com)
4. HE Juan3(3.Department of Pharmacy,Ruijin Hospital Affiliated to School of Medicine,Shanghai Jiaotong University,Shanghai 200025,China hejuanwin@126.com)
ABSTRACT  Objective: To provide solid evidence for optimized treatment of Clostridium difficile bacteremia (CDB) through analyzing successful treatment of one case of blood stream infection by C. difficile. Methods: Clinical manifestations,pathogenesis,risk factors and treatment regimens of one patient with CDB were analyzed,and the features of CDB were investigated based on related literature. Results: This rare case was a 68-year old male patient who had colitis accompanied with chronic perforation and suffered from infection by C. difficile. The patient recovered after anti-infective treatment with vancomycin and metronidazole. Conclusion: The incidence of CDB was relatively lower,but with high mortality. Early rational anti-infective treatment is of paramount importance in the treatment of the disease.
Welcome to PCAR! You are the number 51 reader of this article!
Please cite this article as:
ZHENG Xiaoxiao1,XU Shengqiu1,CHEN Erzhen2,HE Juan3,. Clostridium difficile bacteremia:one case report and literature analysis[J]. Pharmaceutical Care and Research / yao xue fu wu yu yan jiu. 2019; 19(2): 114-117.
References:
1. Mattila E,Arkkila P,Mattila P S,et al.Extraintestinal Clostridium difficile infections[J].Clin Infect Dis,2013,57(6):e148-e153.
2. Kaufman E,Liska D,Rubinshteyn V,et al.Clostridium difficile bacteremia[J].Surg Infect,2013,14(6):559-560.
3. Doufair M,Eckert C,Drieux L,et al.Clostridium difficile bacteremia:report of two cases in French hospitals and comprehensive review of the literature[J].IDCases,2017,8(1):54-62.
4. Lee N Y,Huang Y T,Hsueh P R,et al.Clostridium difficile bacteremia,Taiwan[J].Emerg Infect Dis,2010,16(8):1204-1210.
5. Naggie S,Frederick J,Pien B C,et al.Community-associated Clostridium difficile infection:experience of a veteran affairs medical center in southeastern USA[J].Infection,2010,38(4):297-300.
6. Libby D B,Bearman G.Bacteremia due to Clostridium difficile-review of the literature[J].Int J Infect Dis,2009,13(5):e305-e309.
7. Falcone M,Russo A,Iraci F,et al.Risk factors and outcomes for bloodstream infections secondary to Clostridium difficile infection[J].Antimicrob Agents Chemother,2016,60(1):252-257.
8. Wolf L E,Gorbach S L,Granowitz E V.Extraintestinal Clostridium difficile:10 years’ experience at a tertiary-care hospital[J].Mayo Clin Proc,1998,73(10):943-947.
9. YANG Xuemei,WU Yunfu.Biological characteristics and laboratory diagnosis of Clostridium difficile[J].Chin J Infect Chemother,2013,13(3):232-234.In Chinese with English abstract.
10. YANG Xuemei,WU Yunfu.Infections caused by Clostridium difficile:changing epidemiology and management update[J].Chin J Infect Chemother,2013,13(4):312-316.In Chinese with English abstract.
11. Hagiya H,Kimura K,Ueda A,et al.Infective thoracic aortic aneurysm caused by Clostridium difficile after endovascular aortic repair[J].J Infect Chemother,2016,23(1):62-64.
12. Dauby N,Libois A,van Broeck J,et al.Fatal community-acquired ribotype 002 Clostridium difficile bacteremia[J].Anaerobe,2017,44:1-2.
13. Shah K,Brauch R,Cherabuddi K.Successful treatment of Clostridium difficile bacteremia with aortic mycotic aneurysm in a patient with prior endovascular aortic aneurysm repair[J].Case Rep Infect Dis,2017,8472930.
14. Cohen S H,Gerding D N,Johnson S,et al.Clinical practice guidelines for Clostridium difficile infection in adults:2010 update by the Society for Healthcare Epidemiology of America (SHEA) and the Infectious Diseases Society of America (IDSA)[J].Infect Contr Hosp Epidemiol,2010,31(5):431-455.
15. Chihara S,Shimizu R,Furukata S,et al.Oral vancomycin may have significant absorption in patients with Clostridium difficile colitis[J].Scand J Infect Dis,2011,43(2):149-150.
16. Rybak M,Lomaetro B,Rotschafer J C,et al.Therapeutic monitoring of vancomycin in adult patients:a consensus review of the American Society of Health System Pharmacists,the Infections Diseases Society of America,and the Society of Infections Diseases Pharmacists[J].Am J Health-Syst Pharm,2009,66(1):82-98.
17. Cornely O A,Miller M A,Louie T J,et al.Treatment of first recurrence of Clostridium difficile infection:fidaxomicin versus vancomycin[J].Clin Infect Dis,2012,55(Suppl 2):S154-S161.
《药学服务与研究》杂志社 All Rights Reserved 网站备案号:鲁B2-20061008
·地址:上海市杨浦区长海路168号18号楼东三楼 邮政编码:200433
·联系电话(传真):86-21-65519829, 021-31162330
·电子邮件:PharmCR@vip.163.com
·技术支持:中国康网
管理员入口